BHRC Research Data Guide
Public aggregate summaries
Cross-modality sample overlap
Author: Lucas Toshio Ito
lucas.toshio.ito@gmail.com
Universidade Federal de São Paulo (UNIFESP)
Last updated: March 16, 2026
This chapter summarizes how analytic samples overlap across genotyping and polygenic scores, neuroimaging, DNA methylation, RNA sequencing, miRNA, and whole-genome sequencing resources in BHRC.
All displayed values are aggregate counts or plots. Participant identifiers are used only inside the controlled local analysis workflow to calculate overlap and are not included in the rendered website.
Cross-modality overview
The heatmap below reports overlap between resources at any observed wave, before modality-specific quality control. Each cell shows the shared raw count and the percentage of the row dataset represented by that overlap. The diagonal is therefore 100%. The two interim miRNA sources are combined for this overview and remain separated in the detailed tables below.
Pairwise overlap by index dataset
Percentages in the detailed tables use the named section dataset as the denominator. “Overall” means availability at any observed wave.
Genotyping and polygenic scores
| Genotyping - Overlap with Other Biological Variables | |||||
|---|---|---|---|---|---|
| Variable | Wave 0 (N=2240) | Wave 1 (N=2240) | Wave 2 (N=2240) | Wave 3 (N=2240) | Overall (N=2240) |
| Neuroimaging | 731 (32.6%) | 461 (20.6%) | 416 (18.6%) | 767 (34.2%) | 1250 (55.8%) |
| DNA Methylation | 367 (16.4%) | 369 (16.5%) | 325 (14.5%) | 0 (0.0%) | 455 (20.3%) |
| mRNA Sequencing | 580 (25.9%) | 437 (19.5%) | 0 (0.0%) | 0 (0.0%) | 739 (33.0%) |
| Serum EV-miRNA (Jessica) | 0 (0.0%) | 120 (5.4%) | 120 (5.4%) | 0 (0.0%) | 0 (0.0%) |
| Serum EV-miRNA (Yanka) | 58 (2.6%) | 132 (5.9%) | 132 (5.9%) | 132 (5.9%) | 0 (0.0%) |
| Serum EV-miRNA (All) | 58 (2.6%) | 198 (8.8%) | 198 (8.8%) | 132 (5.9%) | 198 (8.8%) |
| Whole Genome Sequencing (WGS) | 2196 (98.0%) | 2196 (98.0%) | 2196 (98.0%) | 2196 (98.0%) | 2196 (98.0%) |
Neuroimaging
| Neuroimaging - Overlap with Other Biological Variables | |||||
|---|---|---|---|---|---|
| Variable | Wave 0 (N=743) | Wave 1 (N=466) | Wave 2 (N=418) | Wave 3 (N=828) | Overall (N=1321) |
| Genotyping | 731 (98.4%) | 461 (98.9%) | 416 (99.5%) | 767 (92.6%) | 1250 (94.6%) |
| DNA Methylation | 369 (49.7%) | 371 (79.6%) | 325 (77.8%) | 0 (0.0%) | 457 (34.6%) |
| mRNA Sequencing | 570 (76.7%) | 415 (89.1%) | 0 (0.0%) | 0 (0.0%) | 743 (56.2%) |
| Serum EV-miRNA (Jessica) | 0 (0.0%) | 116 (24.9%) | 117 (28.0%) | 0 (0.0%) | 0 (0.0%) |
| Serum EV-miRNA (Yanka) | 58 (7.8%) | 126 (27.0%) | 105 (25.1%) | 123 (14.9%) | 0 (0.0%) |
| Serum EV-miRNA (All) | 58 (7.8%) | 191 (41.0%) | 171 (40.9%) | 123 (14.9%) | 198 (15.0%) |
| Whole Genome Sequencing (WGS) | 734 (98.8%) | 466 (100.0%) | 417 (99.8%) | 790 (95.4%) | 1275 (96.5%) |
Methylation
| DNA Methylation - Overlap with Other Biological Variables | ||||
|---|---|---|---|---|
| Variable | Wave 0 (N=369) | Wave 1 (N=371) | Wave 2 (N=326) | Overall (N=457) |
| Genotyping and Polygenic Scores | 367 (99.5%) | 369 (99.5%) | 325 (99.7%) | 455 (99.6%) |
| Neuroimaging | 369 (100.0%) | 371 (100.0%) | 325 (99.7%) | 457 (100.0%) |
| mRNA Sequencing | 347 (94.0%) | 339 (91.4%) | 0 (0.0%) | 450 (98.5%) |
| Serum EV-miRNA (Jessica) | 0 (0.0%) | 114 (30.7%) | 117 (35.9%) | 0 (0.0%) |
| Serum EV-miRNA (Yanka) | 58 (15.7%) | 113 (30.5%) | 103 (31.6%) | 0 (0.0%) |
| Serum EV-miRNA (All) | 58 (15.7%) | 178 (48.0%) | 169 (51.8%) | 183 (40.0%) |
| Whole Genome Sequencing (WGS) | 369 (100.0%) | 371 (100.0%) | 326 (100.0%) | 457 (100.0%) |
RNA sequencing
| RNA-seq - Overlap with Other Biological Variables | |||
|---|---|---|---|
| Variable | Wave 0 (N=586) | Wave 1 (N=440) | Overall (N=746) |
| Genotyping and Polygenic Scores | 580 (99.0%) | 437 (99.3%) | 739 (99.1%) |
| Neuroimaging | 570 (97.3%) | 415 (94.3%) | 743 (99.6%) |
| DNA Methylation | 347 (59.2%) | 339 (77.0%) | 450 (60.3%) |
| Serum EV-miRNA (Jessica) | 0 (0.0%) | 110 (25.0%) | 0 (0.0%) |
| Serum EV-miRNA (Yanka) | 56 (9.6%) | 120 (27.3%) | 0 (0.0%) |
| Serum EV-miRNA (All) | 56 (9.6%) | 182 (41.4%) | 193 (25.9%) |
| Whole Genome Sequencing (WGS) | 584 (99.7%) | 440 (100.0%) | 744 (99.7%) |
miRNA (Jessica)
| miRNA (Jessica) - Overlap with Other Biological Variables | |||
|---|---|---|---|
| Variable | Wave 1 (N=120) | Wave 2 (N=120) | Overall (N=120) |
| Genotyping and Polygenic Scores | 120 (100.0%) | 120 (100.0%) | 120 (100.0%) |
| Neuroimaging | 116 (96.7%) | 117 (97.5%) | 120 (100.0%) |
| DNA Methylation | 114 (95.0%) | 117 (97.5%) | 118 (98.3%) |
| mRNA Sequencing | 110 (91.7%) | 0 (0.0%) | 117 (97.5%) |
| Serum EV-miRNA (Yanka) | 54 (45.0%) | 54 (45.0%) | 0 (0.0%) |
| Serum EV-miRNA (All) | 120 (100.0%) | 120 (100.0%) | 120 (100.0%) |
| Whole Genome Sequencing (WGS) | 120 (100.0%) | 120 (100.0%) | 120 (100.0%) |
miRNA (Yanka)
| miRNA (Yanka) - Overlap with Other Biological Variables | |||||
|---|---|---|---|---|---|
| Variable | Wave 0 (N=58) | Wave 1 (N=132) | Wave 2 (N=132) | Wave 3 (N=132) | Overall (N=132) |
| Genotyping and Polygenic Scores | 58 (100.0%) | 132 (100.0%) | 132 (100.0%) | 132 (100.0%) | 132 (100.0%) |
| Neuroimaging | 58 (100.0%) | 126 (95.5%) | 105 (79.5%) | 123 (93.2%) | 132 (100.0%) |
| DNA Methylation | 58 (100.0%) | 113 (85.6%) | 103 (78.0%) | 0 (0.0%) | 117 (88.6%) |
| mRNA Sequencing | 56 (96.6%) | 120 (90.9%) | 0 (0.0%) | 0 (0.0%) | 128 (97.0%) |
| Serum EV-miRNA (Jessica) | 0 (0.0%) | 54 (40.9%) | 54 (40.9%) | 0 (0.0%) | 0 (0.0%) |
| Serum EV-miRNA (All) | 58 (100.0%) | 132 (100.0%) | 132 (100.0%) | 132 (100.0%) | 132 (100.0%) |
| Whole Genome Sequencing (WGS) | 58 (100.0%) | 132 (100.0%) | 132 (100.0%) | 132 (100.0%) | 132 (100.0%) |
miRNA (combined)
| miRNA (All) - Overlap with Other Biological Variables | |||||
|---|---|---|---|---|---|
| Variable | Wave 0 (N=58) | Wave 1 (N=198) | Wave 2 (N=198) | Wave 3 (N=132) | Overall (N=198) |
| Genotyping and Polygenic Scores | 58 (100.0%) | 198 (100.0%) | 198 (100.0%) | 132 (100.0%) | 198 (100.0%) |
| Neuroimaging | 58 (100.0%) | 191 (96.5%) | 171 (86.4%) | 123 (93.2%) | 198 (100.0%) |
| DNA Methylation | 58 (100.0%) | 178 (89.9%) | 169 (85.4%) | 0 (0.0%) | 183 (92.4%) |
| mRNA Sequencing | 56 (96.6%) | 182 (91.9%) | 0 (0.0%) | 0 (0.0%) | 193 (97.5%) |
| Serum EV-miRNA (Jessica) | 0 (0.0%) | 120 (60.6%) | 120 (60.6%) | 0 (0.0%) | 0 (0.0%) |
| Serum EV-miRNA (Yanka) | 58 (100.0%) | 132 (66.7%) | 132 (66.7%) | 132 (100.0%) | 0 (0.0%) |
| Whole Genome Sequencing (WGS) | 58 (100.0%) | 198 (100.0%) | 198 (100.0%) | 132 (100.0%) | 198 (100.0%) |
Whole-genome sequencing (WGS)
| WGS - Overlap with Other Biological Variables | |||||
|---|---|---|---|---|---|
| Variable | Wave 0 (N=2279) | Wave 1 (N=2279) | Wave 2 (N=2279) | Wave 3 (N=2279) | Overall (N=2279) |
| Genotyping and Polygenic Scores | 2196 (96.4%) | 2196 (96.4%) | 2196 (96.4%) | 2196 (96.4%) | 2196 (96.4%) |
| Neuroimaging | 734 (32.2%) | 466 (20.4%) | 417 (18.3%) | 790 (34.7%) | 1275 (55.9%) |
| DNA Methylation | 369 (16.2%) | 371 (16.3%) | 326 (14.3%) | 0 (0.0%) | 457 (20.1%) |
| mRNA Sequencing | 584 (25.6%) | 440 (19.3%) | 0 (0.0%) | 0 (0.0%) | 744 (32.6%) |
| Serum EV-miRNA (Jessica) | 0 (0.0%) | 120 (5.3%) | 120 (5.3%) | 0 (0.0%) | 0 (0.0%) |
| Serum EV-miRNA (Yanka) | 58 (2.5%) | 132 (5.8%) | 132 (5.8%) | 132 (5.8%) | 0 (0.0%) |
| Serum EV-miRNA (All) | 58 (2.5%) | 198 (8.7%) | 198 (8.7%) | 132 (5.8%) | 198 (8.7%) |